|
Volumn 53, Issue 5, 2000, Pages 203-205
|
Evaluation of Viroseq™-HIV version 2 for HIV drug resistance
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;
DEOXYURIDINE TRIPHOSPHATE DERIVATIVE;
GUANIDINE;
NUCLEOTIDE;
PROTEINASE;
PROTEINASE INHIBITOR;
RNA DIRECTED DNA POLYMERASE;
RNA DIRECTED DNA POLYMERASE INHIBITOR;
THIOCYANATE;
URACIL DNA GLYCOSYLTRANSFERASE;
VIRUS ENZYME;
VIRUS RNA;
ARTICLE;
CLINICAL ARTICLE;
COMMERCIAL PHENOMENA;
CONTROLLED STUDY;
COST BENEFIT ANALYSIS;
DRUG RESISTANCE;
GENE AMPLIFICATION;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS 1;
JAPAN;
LABORATORY TEST;
NONHUMAN;
REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;
SENSITIVITY AND SPECIFICITY;
VIRAL GENETICS;
VIRUS CULTURE;
VIRUS EXAMINATION;
VIRUS MUTATION;
VIRUS RESISTANCE;
ANTIBIOTIC RESISTANCE;
CLASSIFICATION;
COMPARATIVE STUDY;
DRUG EFFECT;
EVALUATION;
GENETIC PROCEDURES;
GENETICS;
GENOTYPE;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
MUTATION;
VIROLOGY;
ANTI-HIV AGENTS;
DRUG RESISTANCE, MICROBIAL;
GENETIC TECHNIQUES;
GENOTYPE;
HIV INFECTIONS;
HIV-1;
HUMANS;
MUTATION;
|
EID: 0034351789
PISSN: 13446304
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (7)
|
References (1)
|